Paliperidone Description of the Psychopharmacological medication agent including brand and generic names and appropriate FDA indication uses

Paliperidone is classified as an atypical antipsychotic. Its trade name is given as Invega and it is regarded as a metabolite of risperidone since the two medications have similar side effects and even bind to dopamine and serotonin receptors on though at different ratios (Mathews et al., 2020). This is a drug used to manage patients with schizoaffective and schizophrenia disorders.It has been manufactured and marketed by Janssen Pharmaceuticals. Any supporting, valid and reliable research for non-FDA uses Existing evidence shows that there are existing extendable release tablets for Invega that are used in managing patients with schizoaffective disorder where it is used as a monotherapy and it is further used as adjunct in managing mood stabilizers and it is also used as an antidepressant (Mathews et al., 2020). Paliperidone palmitate, which features as a second- generation antipsychotic drug is used as a long-acting injectable in managing patients with schizophrenia. It is given as a maintenance dose on either deltoid or gluteal muscle. Drug classification Paliperidone is classified as a second generation (atypical) antipsychotic drug. The medication mechanism of action The mechanism of action of Invega is usually as a result of its antagonistic effect on both dopamine or D2 or Serotonin receptors that are present in the brain. Once the receptors that aid in transmission of dopamine or serotonin neurotransmitters are blocked, the activity of the brain

3 is usually normalized hence reducing or normalizing the symptoms that patients with schizophrenia or schizoaffective disorder present with (Mathews et al., 2020).Additionally, the drug also binds on the alpha-1 and alpha-2 adrenergic receptors and also H1 histaminergic receptors triggering sedation, hypertension as well as tachycardia